Another $VTAE,
Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Receives Consensus Recommendation of “Buy” from Brokerages
March 14th, 2016 - By Faye Duncan - 0 comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE) has been given an average rating of “Buy” by the six brokerages that are covering the stock, Market Beat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $21.50.
VTAE has been the topic of a number of recent research reports. Stifel Nicolaus lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 4th. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Vitae Pharmaceuticals in a research note on Friday, December 11th. Piper Jaffray reiterated a “buy” rating and set a $18.00 price objective on shares of Vitae Pharmaceuticals in a research note on Tuesday, December 29th. Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 5th.
In other news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 133,000 shares of the company’s stock, valued at approximately $2,407,000. Candriam Luxembourg S.C.A. owned approximately 0.61% of Vitae Pharmaceuticals as of its most recent filing with the SEC.
Vitae Pharmaceuticals (NASDAQ:VTAE) traded up 2.31% during trading on Monday, reaching $4.88. 573,488 shares of the company’s stock were exchanged. The firm’s market cap is $106.73 million. The stock’s 50 day moving average price is $8.57 and its 200 day moving average price is $12.03. Vitae Pharmaceuticals has a 52-week low of $4.15 and a 52-week high of $18.71.
Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.10. The company earned $0.09 million during the quarter, compared to the consensus estimate of $0.14 million. Vitae Pharmaceuticals’s revenue for the quarter was down 42.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) EPS for the current fiscal year.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Receives Consensus Recommendation of “Buy” from Brokerages
March 14th, 2016 - By Faye Duncan - 0 comments
Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE) has been given an average rating of “Buy” by the six brokerages that are covering the stock, Market Beat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $21.50.
VTAE has been the topic of a number of recent research reports. Stifel Nicolaus lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 4th. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Vitae Pharmaceuticals in a research note on Friday, December 11th. Piper Jaffray reiterated a “buy” rating and set a $18.00 price objective on shares of Vitae Pharmaceuticals in a research note on Tuesday, December 29th. Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 5th.
In other news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 133,000 shares of the company’s stock, valued at approximately $2,407,000. Candriam Luxembourg S.C.A. owned approximately 0.61% of Vitae Pharmaceuticals as of its most recent filing with the SEC.
Vitae Pharmaceuticals (NASDAQ:VTAE) traded up 2.31% during trading on Monday, reaching $4.88. 573,488 shares of the company’s stock were exchanged. The firm’s market cap is $106.73 million. The stock’s 50 day moving average price is $8.57 and its 200 day moving average price is $12.03. Vitae Pharmaceuticals has a 52-week low of $4.15 and a 52-week high of $18.71.
Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.10. The company earned $0.09 million during the quarter, compared to the consensus estimate of $0.14 million. Vitae Pharmaceuticals’s revenue for the quarter was down 42.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) EPS for the current fiscal year.
Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
1
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
